Shanghai Nianxing Industrial Co., Ltd
China
Product Name: TTT-28
Price:
Purity: 99.0%
Stocking Period: 10 Day
Contact: Yang

1609138-51-3

1609138-51-3 structure

1609138-51-3 structure

Name: TTT-28
Chemical Name: TTT-28
CAS Number: 1609138-51-3
Molecular Formula: C₃₁H₃₁N₃O₆S
Molecular Weight: 573.66
Catalog: Research Areas Cancer
Create Date: 2019-08-03 21:21:59
Modify Date: 2024-01-13 13:36:36
TTT-28 is a synthesized thiazole-valine peptidomimetic, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1)-mediated Multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1[1].

Name	TTT-28

Description	TTT-28 is a synthesized thiazole-valine peptidomimetic, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1)-mediated Multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	TTT-28 (0-100 μM; 72 hours) reverses ABCB1-mediated MDR in drug selected SW620/Ad300 cells and transfected HEK293/ABCB1 cells; the IC50s of TTT-28 in CCD-18Co, SW620 and SW620/Ad300 cells are 213.4±11.0 μM, 89.4±3.9 μM and 92.0±5.0 μM, respectively[1]. TTT-28 (10 μM; 2 hours) raises the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells[1]. TTT-28 (10 μM; 0-72 hours) does not interfer with the expression level and localization of ABCB1, it results from blocking the efflux function of ABCB1[1]. TTT-28 (0-40 μM; 2 hours) interacts at the drug-substrate-binding site and actives the ATPase activity of ABCB1 in a concentration-dependent fashion[1]. Cell Viability Assay[1] Cell Line: SW620 cells, SW620/Ad300 cells Concentration: 0.1 μM, 1 μM, 10 μM, 100 μM Incubation Time: 72 hours Result: Decreased the resistance fold of ABCB1 substrates (Paclitaxel, Doxorubicin, Vincristine) in SW620/Ad300 cells compared to SW620 cells.
In Vivo	TTT-28 (deliver orally; 30 mg/kg; every 3 rd day; 18 days) potentiates the anticancer activity of paclitaxel due to its inhibitory effect on the efflux function of ABCB1, it enhances the inhibitory effect of paclitaxel on the growth of SW620/Ad300 tumor and promoted apoptosis[1]. Animal Model: 5-10 week Male athymic NCR (nu/nu) nude mice ABCB1 overexpressing tumor xenograft model with SW620/Ad300 cells Dosage: 30 mg/kg Administration: Deliver orally; every 3rd day; 18 days Result: Lead to higher intratumoral accumulation of paclitaxel in tumors.
References	[1]. Wang YJ, et al. Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Sci Rep. 2017 Feb 9;7:42106.

Molecular Formula	C₃₁H₃₁N₃O₆S
Molecular Weight	573.66